H.C. Wainwright Reiterates Buy Rating on Albireo Pharma (ALBO), Estimates Peak Bylvay PFIC Sales of $446M

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $80.00 price target on Albireo Pharma (NASDAQ: ALBO), following NICE's recommendation of Bylvay for all PFIC types.

The analyst quotes: "We employ an rNPV model to value ALBO shares. We estimate the risk-adjusted per share value as the sum of: (1) Bylvay for PFIC at $45.72 (100% PoS; $446M peak revenues in 2031E); (2) Bylvay in BA at $21.53 (55% PoS; $1.16B peak revenues in 2031E); and (3) Bylvay in ALGS at $12.70 (55% PoS; $439M peak revenues in 2031E). The key risks to our rating and PT include: (1) clinical trial failures or equivocal results; (2) inability to secure U.S. regulatory approval of Bylvay in ALGS or BA; (3) meaningful delays to the expected development or regulatory timelines for each program; (4) growth of Bylvay sales in PFIC meaningfully below our expectations; and (5) inability to access the equity capital markets at reasonable terms."

For an analyst ratings summary and ratings history on Albireo Pharma click here. For more ratings news on Albireo Pharma click here.

Shares of Albireo Pharma closed at $32.84 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat